No abstract available.
Female ; Metrorrhagia*

No abstract available.
Female ; Metrorrhagia*

No abstract available.
Female ; Metrorrhagia*

OBJECTIVE: To analyze the clinical experiences of patients who treated with levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis associated with dysmenorrhea and/or menorrhagia. METHODS: The LNG-IUS was inserted into 103 patients who were diagnosed with adenomyosis on ultrasound examination and suffered from dysmenorrhea or menorrhagia at CHA Gangnam Medical Center between January 2009 and December 2009. Symptomatic changes of dysmenorrhea and menorrhagia, side effects, and failure rates were evaluated, retrospectively. RESULTS: During the follow-up periods, dysmenorrhea was improved in 91.4% and menorrhagia was improved in 90.4% of patients. Most common side effects were prolonged vaginal spotting in 41 (39.8%), and expulsion of LNG-IUS in 32 (31.1%) patients. Six (5.7%) patients were premature removal of LNG-IUS and 9 (8.5%) patients were underwent hysterectomy. Overall 77 (74.8%) patients continued to use of LNG-IUS. CONCLUSION: The LNG-IUS is effective treatment option for management of dysmenorrhea and menorrhagia for patients with clinical diagnosis of adenomyosis. It seemed to be an alternative treatment method before hysterectomy.
Adenomyosis ; Dysmenorrhea ; Female ; Follow-Up Studies ; Humans ; Hysterectomy ; Menorrhagia ; Metrorrhagia

Leiomyosarcomas comprise fewer than 2% of all malignant vaginal neoplasms. Due to their rarity, treatment for vaginal leiomyosarcomas have not been determined. We describe a 66 year old woman with vaginal leiomyosarcoma, which presented as a large palpable mass with vaginal spotting. Complete surgical excision was accomplished and after surgery, she underwent radiation therapy. Tumor recurrence was not detected for the last 5 years and now her general condition is very good. This is a rare case of leiomyosarcoma arising in vagina and we report the results of successful treatment.
Female ; Humans ; Leiomyosarcoma ; Metrorrhagia ; Recurrence ; Vagina ; Vaginal Neoplasms

Leiomyosarcomas comprise fewer than 2% of all malignant vaginal neoplasms. Due to their rarity, treatment for vaginal leiomyosarcomas have not been determined. We describe a 66 year old woman with vaginal leiomyosarcoma, which presented as a large palpable mass with vaginal spotting. Complete surgical excision was accomplished and after surgery, she underwent radiation therapy. Tumor recurrence was not detected for the last 5 years and now her general condition is very good. This is a rare case of leiomyosarcoma arising in vagina and we report the results of successful treatment.
Female ; Humans ; Leiomyosarcoma ; Metrorrhagia ; Recurrence ; Vagina ; Vaginal Neoplasms

OBJECTIVE: to test the safety of ultrasound imaging guided high intensity focused ultrasound (HIFU) to ablate uterine myoma. METHODS: From September 2008 to February 2009, patients with dysmenorrhea and/or menorrhagia for uterine myomas had been enrolled. HIFU ablation was performed at 1 MHz. 400 W/cm2 of pulses were delivered for 150 m second with 150 m second interval at the target point for 70 cycles. This process was repeated on a point by point basis. After one slice was treated, the target was shifted 4 mm laterally. If patient were complaining of pain, the procedures were stopped for a while. RESULTS: The distribution of age was 29~48 years old, and of longest diameter was 36.0~115.0 mm, and of target distance from skin was 55~100 mm, and of number of treatment was 2~6. Nobody gave up the procedure for pain or any other reason. The procedures took 40 to 60 minutes for a slice. One or three slices were treated in a day. All patients went home after HIFU without medication. Nobody reported any clinically severe complications. Everybody returned to normal activities 1 day after the procedure. Nobody complained of vaginal spotting after one cycle of menstruation. CONCLUSION: Ultrasound imaging-guided HIFU treatment appears to be safe to ablate the uterine myomas.
Dysmenorrhea ; Female ; Humans ; Menorrhagia ; Menstruation ; Metrorrhagia ; Myoma ; Skin

Oral contraceptive user had less menstrual blood loss, which reduced the risk of iron deificiency anemia by 50%. The incidence of menorrhagia, irregular menses and intermenstrual bleeding is also singificantly reduced in the user of oral contraceptives. In most women with leiomyomas, low-dose oral contraceptive use provide the noncontraceptive benefit of a reduction of menstrual flow, with resultant improvement in hematocrit. So, we confirmed that anemic leiomyoma patients with oral contraceptive use showed autotransfusion effects given by preoperative administration orally during some period.
Anemia ; Blood Transfusion, Autologous* ; Contraceptives, Oral ; Female ; Hematocrit ; Humans ; Incidence ; Iron ; Leiomyoma ; Menorrhagia ; Metrorrhagia ; Myoma

PURPOSE: We investigated the menstrual features of adolescent school girls to know the characteristics of menarche and dysfunctional uterine bleeding in adolescents. METHODS: In March, 2001, 1,434 primary and middle school girls(10-15 years of age) in Ansan City were investigated for the menacheal age and several aspects of menstruation through questionnaire. RESULTS: Mean age of the total subjects were 13.0+/-1.2 years of age, and 68.4% of them experienced menarche. 32.2% experienced menarche after age 12, but 82.9% experienced it after age 13. Mixed type(regular and irregular) menstrual cycle was the most common(35.3%), and changing type(irregular to regular) was 27.6%. In changing type, the mean duration of cycle stabilization was 6.6+/-4.9 months. The most common menstrual cycle was 'within 26-30 days'(31.4%). Abnormal cycles such as 'equal or less than 20 days' and 'equal or more than 41 days' were 17.2% and 2.0%, respectively. The most common menstrual duration was '5-6 days'(44.7%). 7.6% of the subjects experienced short or long menstrual duration. Among the subjects, only 4.0% visited the hospital with menstrual problems. The visiting reasons were 'irregular menstrual cycles'(38.5%), 'dysmenorrhea'(28.2%), 'menorrhagia'(12.8%), and 'hypermenorrhea'(28.2%). CONCLUSION: Most adolescent girls in our study experienced menarche until 13 years of age and some of them got early menarche at the age of 9. Many of them had irregular or unstable menstrual cycles after menarche at any age, but only few of them visited a health care provider. We suggest the careful attention of pediatricians, parents and teachers to the early detection and proper treatment of menstrual problems in adolescent girls.
Adolescent* ; Female ; Female* ; Gyeonggi-do* ; Health Personnel ; Humans ; Menarche* ; Menstrual Cycle ; Menstruation ; Metrorrhagia* ; Parents ; Surveys and Questionnaires

The concept of mosaicism has been used to explain different cutaneous patterns, such as the lines of Blaschko, the checkerboard pattern, the phylloid pattern, and a patchy pattern. Many mosaic patterns are caused by loss of heterozygosity, the genetic mechanism by which a heterozygous somatic cell becomes either homozygous or hemizygous. A particular form of loss of heterozygosity is twin spotting, which give rise to two contrary homozygous daughter cells. The concept of twin spotting has been used for some of these human phenotypes, which are characterized by the co-occurrence of two different nevi, including nevus vascularis mixtus. Nevus vascularis mixtus is a rare vascular malformation characterized by the coexistence of a nevus anemicus and a nevus telangiectaticus, and can be associated with extra-cutaneous anomalies, such as cerebral malformations. Herein, we report a 6-year-old girl with paired cutaneous vascular nevi telangiectaticus, anemicus, and nevus vascularis mixtus, that were distributed on the left side of her chest and left arm, without other systemic and neurologic anomalies.
Arm ; Child ; Female ; Humans ; Loss of Heterozygosity ; Metrorrhagia ; Mosaicism ; Nevus* ; Nuclear Family ; Phenotype ; Thorax ; Twins ; Vascular Malformations